Compared side by side
TB-500 vs KPV: how they differ
The short answer
They cover different parts of healing: TB-500, the 7-amino-acid stretch of thymosin beta-4 that binds actin, helps repair cells reach injured tissue, and KPV, three amino acids from the tail of α-MSH, blocks NF-κB, the master switch for inflammatory signals, in cell and mouse studies. TB-500’s own research is a few animal studies, and no human study has tested KPV. TB-500 runs with a twice-weekly loading phase; KPV is taken daily, by injection or by mouth.
Side by side
| Compared | TB-500 | KPV |
|---|---|---|
| Category | Healing & recovery | Healing & recovery |
| Also known as | Thymosin Beta-4 Fragment, TB4 | Lys-Pro-Val, α-MSH tripeptide |
| What it is | A fragment of thymosin beta-4, a protein your body uses for cell repair. | One of the smallest bioactive peptides: three amino acids from the tail end of α-MSH. |
| How it works | Synthetic fragment of Thymosin Beta-4: Ac-LKKTETQ, the 7-amino-acid stretch (residues 17–23) that binds actin. The whole protein holds actin building blocks back from forming filaments, a reserve cells draw on when they move. In lab and rodent studies the fragment drew blood-vessel cells, sped wound repair in aged mice and strengthened repaired tendons in rats; the anti-inflammatory findings are for the whole protein. Loading phase 2x/week then drop to maintenance. | C-terminal tripeptide of α-MSH. A potent anti-inflammatory in cell and mouse studies that works mainly inside cells rather than through melanocortin receptors: it enters through the PepT1 transporter and blocks NF-κB signaling. In mice it eased colitis and damped allergic skin reactions; as eye drops it sped corneal wound healing in rabbits; in lab dishes it slowed Staphylococcus aureus and Candida albicans. |
| Commonly reported | Stubborn soft-tissue injuries loosening up, with range of motion returning over a few weeks. Its own research is a few animal studies; the human trials tested the whole protein. Often paired with BPC-157. | A calmer gut and calmer skin. No human study has tested it yet. |
| Studied range | Research range: 1–2.5 mg. Studied in research — not a recommendation. | Research range: 100–300 mcg. Studied in research — not a recommendation. |
| How often | 2x/week loading, 1–2mg/week maintenance | Daily |
| Half-life | ~0.5–2 hours (measured for the whole protein, thymosin beta-4, given IV to healthy volunteers; TB-500 itself has never been measured in people) | Not measured: no half-life for KPV has been published, in people or animals |
| Route | SubQ injection, IM injection | SubQ injection, Oral |
| Typical run | Loading phase 2x/week for 4–6 weeks, then maintenance 1x/week or stop. Common to cycle 6–8 weeks on, time off. | 4–8 weeks typical for gut protocols. Can reassess after each cycle. |
| Evidence | Emerging: primarily preclinical / limited human data | Emerging: primarily preclinical / limited human data |
| Common side effects | Injection site reaction, fatigue, nausea, headache, lethargy | Injection site irritation, mild nausea |
- Category
- TB-500Healing & recovery
- KPVHealing & recovery
- Also known as
- TB-500Thymosin Beta-4 Fragment, TB4
- KPVLys-Pro-Val, α-MSH tripeptide
- What it is
- TB-500A fragment of thymosin beta-4, a protein your body uses for cell repair.
- KPVOne of the smallest bioactive peptides: three amino acids from the tail end of α-MSH.
- How it works
- TB-500Synthetic fragment of Thymosin Beta-4: Ac-LKKTETQ, the 7-amino-acid stretch (residues 17–23) that binds actin. The whole protein holds actin building blocks back from forming filaments, a reserve cells draw on when they move. In lab and rodent studies the fragment drew blood-vessel cells, sped wound repair in aged mice and strengthened repaired tendons in rats; the anti-inflammatory findings are for the whole protein. Loading phase 2x/week then drop to maintenance.
- KPVC-terminal tripeptide of α-MSH. A potent anti-inflammatory in cell and mouse studies that works mainly inside cells rather than through melanocortin receptors: it enters through the PepT1 transporter and blocks NF-κB signaling. In mice it eased colitis and damped allergic skin reactions; as eye drops it sped corneal wound healing in rabbits; in lab dishes it slowed Staphylococcus aureus and Candida albicans.
- Commonly reported
- TB-500Stubborn soft-tissue injuries loosening up, with range of motion returning over a few weeks. Its own research is a few animal studies; the human trials tested the whole protein. Often paired with BPC-157.
- KPVA calmer gut and calmer skin. No human study has tested it yet.
- Studied range
- TB-500Research range: 1–2.5 mg. Studied in research — not a recommendation.
- KPVResearch range: 100–300 mcg. Studied in research — not a recommendation.
- How often
- TB-5002x/week loading, 1–2mg/week maintenance
- KPVDaily
- Half-life
- TB-500~0.5–2 hours (measured for the whole protein, thymosin beta-4, given IV to healthy volunteers; TB-500 itself has never been measured in people)
- KPVNot measured: no half-life for KPV has been published, in people or animals
- Route
- TB-500SubQ injection, IM injection
- KPVSubQ injection, Oral
- Typical run
- TB-500Loading phase 2x/week for 4–6 weeks, then maintenance 1x/week or stop. Common to cycle 6–8 weeks on, time off.
- KPV4–8 weeks typical for gut protocols. Can reassess after each cycle.
- Evidence
- TB-500Emerging: primarily preclinical / limited human data
- KPVEmerging: primarily preclinical / limited human data
- Common side effects
- TB-500Injection site reaction, fatigue, nausea, headache, lethargy
- KPVInjection site irritation, mild nausea
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
TB-500
- Day 1–7 Week one: set your baseline
- Day 7–14 Stiffness often starts to ease
- Day 14–28 Load tolerance often picks up
- Day 28–42 Gains slow, repair keeps going
- Day 42–56 Weeks 6 to 8: how far it's come
KPV
- Day 1–7 Week one: your starting point
- Day 7–21 Users often report a calmer gut
- Day 21–42 Some report calmer skin
- Day 42–56 Weeks 6 to 8: taking stock
Together or one or the other
TB-500 and KPV are a common stack: they’re together in the KLOW stack.
- KLOW: GLOW plus KPV — four repair peptides in one vial (KPV, BPC-157, TB-500 and GHK-Cu).
Questions people ask
How long do TB-500 and KPV last?
The half-life of TB-500 is ~0.5–2 hours (measured for the whole protein, thymosin beta-4, given IV to healthy volunteers; TB-500 itself has never been measured in people). The half-life of KPV is not measured: no half-life for KPV has been published, in people or animals.
How often are TB-500 and KPV taken?
TB-500: 2x/week loading, 1–2mg/week maintenance. Routes: SubQ injection, IM injection. KPV: daily. Routes: SubQ injection, oral.
How are TB-500 and KPV dosed in research?
The research range for TB-500 is 1–2.5 mg. The research range for KPV is 100–300 mcg. Studied in research — not a recommendation.
What are the common side effects of TB-500 and KPV?
For TB-500, the library lists: injection site reaction, fatigue, nausea, headache, lethargy. For KPV: injection site irritation, mild nausea.
Are TB-500 and KPV taken together?
TB-500 and KPV are a common stack: they’re together in the KLOW stack.